ClinicalTrials.gg

Program

LY03017

A development code.

Its studies are mostly in Hallucinations · Alzheimer Disease, led by Luye Pharma Group.

Furthest: phase 1, since Apr 24, 20243 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Luye Pharma Group32 open or runningphase 1since Apr 24, 2024Apr 24, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2024First study: phase 1 study in HallucinationsFirst studyNCT06388551 · 60 enrolled · China
  2. Jan 20, 2025Phase 1 study in Alzheimer's Disease PsychosisNCT06793995 · 26 planned · China
  3. May 12, 2025Phase 1 study in HallucinationsNCT06980207 · 40 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06980207Hallucinations · China1Not yet recruitingOct 202540
NCT06793995Alzheimer's Disease Psychosis · China1Not yet recruitingOct 31, 202526
NCT06388551Hallucinations · China1UNKNOWNMar 30, 202560

How it is read

Names in the registry

  • “LY03017”, 4 entries

Codes read as this program: LY03017.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.